Hydroxychloroquine
Prenatal hydroxychloroquine exposure not linked to major structural birth defects
The use of hydroxychloroquine during pregnancy is not associated with structural birth defects or any other outcomes, save for birth head circumference, according to data published in Arthritis & Rheumatology.
Hydroxychloroquine prescribers 'should be vigilant' for potential cardiac toxicity
Rheumatologists who prescribe hydroxychloroquine or chloroquine should be aware of their potential cardiac toxicity, especially in high-risk patients with rheumatic disease, according to an American College of Rheumatology white paper.
Higher dosing, duration of use intensifies risk for hydroxychloroquine retinopathy
The risk for hydroxychloroquine retinopathy increases with higher dosing per actual and ideal body weight, and with longer duration of use, according to data presented at ACR Convergence 2021.
Reducing, stopping hydroxychloroquine spikes flare risk for lupus patients in remission
Hydroxychloroquine maintenance, compared with reducing or discontinuing, is associated with a lower risk for flare among patients with systemic lupus erythematosus in remission or very low disease activity, according to data presented here.
'Promising treatments' for Sjögren’s syndrome may enter clinical use in 3-5 years
It is likely that one or more “promising treatments” currently being investigated for Sjögren’s syndrome will come into use within the next 3 to 5 years, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.
Top in rheumatology: Hydroxychloroquine for COVID-19, the delta surge
New data support halting the use of hydroxychloroquine for COVID-19, which has been prescribed more than 560,000 times in 2021 alone to prevent and treat SARS-CoV-2 infection, according to an expert.
'Premature, avoidable deaths' renew plea to halt prescribing hydroxychloroquine for COVID-19
Updated evidence “strongly supports” ending the use of hydroxychloroquine for either preventing or treating COVID-19, due to a lack of benefits combined with potentially fatal cardiovascular complications, according to a meta-analysis.
From 'success' to 'madness': Rheumatologists share their worldwide COVID-19 experiences
In a session here, attendees heard global perspectives from their rheumatology colleagues in Australia, Canada, Puerto Rico, the Caribbean, Brazil and India.
‘What we see that kills patients’: Managing cardiovascular event risk in lupus nephritis
Managing cardiovascular event risk is critical to preventing morbidity and mortality in lupus nephritis, especially among groups at increased risk for the disease, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.
Retracted COVID-19 study remains ‘widely cited’ in medical literature
A retracted New England Journal of Medicine study on the link between CVD, renin-angiotensin–aldosterone system inhibitor therapy and COVID-19 outcomes continues to be “widely cited” in medical literature, researchers wrote.